Guidelines & Consensus
Adjuvant Radiotherapy in Stage III dMMR Endometrial Cancer: Evidence and Clinical Perspectives
Macchia et alEClinicalMedicine

Although current clinical guidelines incorporate chemo-immunotherapy for stage III–IV mismatch repair-deficient (dMMR) endometrial cancer, available evidence supporting the omission of adjuvant radiotherapy remains insufficient. Pelvic radiotherapy plays a central role in achieving durable locoregional control in high-risk endometrial cancer, and there is a lack of robust randomized evidence demonstrating the equivalence of systemic therapy alone compared with regimens including radiotherapy.
Key clinical trials have not directly addressed radiotherapy omission in this population. The PORTEC-3 trial delivered radiotherapy across both treatment cohorts and did not evaluate immunotherapy, whereas KEYNOTE-B21 did not randomize radiotherapy delivery. Consequently, neither trial directly evaluated whether radiotherapy can be safely omitted in dMMR high-risk disease. Ongoing studies, including NRG-GY020 and the RAINBO MMRd-GREEN trial, are expected to define the optimal integration of immunotherapy and adjuvant radiotherapy in molecularly stratified cohorts.
Future randomized studies evaluating molecularly stratified populations should assess radiotherapy as an independent treatment variable. In addition to overall survival, clinically relevant endpoints should include locoregional control, recurrence burden, patterns of failure, and quality of life/patient-reported outcomes. Until randomized data become available, clinical adoption of radiotherapy de-escalation requires caution.
Key Takeaways
- Current evidence supporting the omission of adjuvant external beam radiotherapy in stage III mismatch repair-deficient (dMMR) endometrial cancer remains insufficient, indicating that de-escalation strategies should be adopted with caution.
- Neither the PORTEC-3 trial (which administered radiotherapy in both study arms without immunotherapy) nor KEYNOTE-B21 (which did not randomize radiotherapy) directly evaluated the safety of omitting adjuvant radiotherapy.
Read the original sourceEClinicalMedicine
